EA200500672A1 - Содержащие альфузозин композиции с отсроченным высвобождением - Google Patents

Содержащие альфузозин композиции с отсроченным высвобождением

Info

Publication number
EA200500672A1
EA200500672A1 EA200500672A EA200500672A EA200500672A1 EA 200500672 A1 EA200500672 A1 EA 200500672A1 EA 200500672 A EA200500672 A EA 200500672A EA 200500672 A EA200500672 A EA 200500672A EA 200500672 A1 EA200500672 A1 EA 200500672A1
Authority
EA
Eurasian Patent Office
Prior art keywords
functional layer
release
solvate
enantiomers
alphusosin
Prior art date
Application number
EA200500672A
Other languages
English (en)
Inventor
Нарайянан Бадри Висванатан
Санкар Рамакришнан
Раджеев Сингх Рагхуванши
Ашок Рампал
Original Assignee
Рэнбакси Лабораториз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рэнбакси Лабораториз Лимитед filed Critical Рэнбакси Лабораториз Лимитед
Publication of EA200500672A1 publication Critical patent/EA200500672A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям альфузозина или его фармацевтически приемлемой соли, сольвата, энантиомеров или их смесей, которые высвобождают активный ингредиент в течение длительного периода времени. Фармацевтическая композиция может представлять собой оральную лекарственную форму с отсроченным высвобождением, которая включает один функциональный слой и, необязательно, один или более нефункциональных слоев, смежных с одним функциональным слоем. Один функциональный слой включает альфузозин или его фармацевтически приемлемую соль, сольват, энантиомеры или их смеси и один или более ингредиентов, замедляющих высвобождение.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500672A 2002-10-22 2003-10-22 Содержащие альфузозин композиции с отсроченным высвобождением EA200500672A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1056DE2002 2002-10-22
PCT/IB2003/004677 WO2004037228A1 (en) 2002-10-22 2003-10-22 Sustained release compositions containing alfuzosin

Publications (1)

Publication Number Publication Date
EA200500672A1 true EA200500672A1 (ru) 2005-12-29

Family

ID=34631110

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500672A EA200500672A1 (ru) 2002-10-22 2003-10-22 Содержащие альфузозин композиции с отсроченным высвобождением

Country Status (8)

Country Link
US (1) US20060147530A1 (ru)
EP (1) EP1556014A1 (ru)
CN (1) CN1720026A (ru)
AU (1) AU2003278407A1 (ru)
BR (1) BR0315569A (ru)
EA (1) EA200500672A1 (ru)
MX (1) MXPA05004338A (ru)
WO (1) WO2004037228A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
WO2007080509A2 (en) * 2006-01-12 2007-07-19 Wockhardt Ltd Sustained release compositions of alfuzosin
US20070292505A1 (en) * 2006-06-15 2007-12-20 Abrika Pharmaceuticals, Inc. Controlled release alfuzosin hydrochloride formulation
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CN105287422A (zh) * 2015-12-07 2016-02-03 黑龙江省智诚医药科技有限公司 一种盐酸阿夫唑嗪缓释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
EP0938318B1 (fr) * 1996-08-29 2001-05-02 Sanofi-Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu

Also Published As

Publication number Publication date
WO2004037228A1 (en) 2004-05-06
WO2004037228A8 (en) 2004-08-26
EP1556014A1 (en) 2005-07-27
MXPA05004338A (es) 2005-06-22
US20060147530A1 (en) 2006-07-06
AU2003278407A1 (en) 2004-05-13
BR0315569A (pt) 2005-08-30
CN1720026A (zh) 2006-01-11

Similar Documents

Publication Publication Date Title
RU2370495C2 (ru) Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора
NO20043367L (no) Oralt farmasoytisk preparat
HUP0302876A2 (hu) Gyógyszerészeti kiszerelés
EA200501586A1 (ru) Фармацевтические продукты
RS54670B1 (en) SOLID DOSAGE FORMULATION OF FENTANIL WITH IMPROVED BUCHAL ADSORPTION
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
EA200400471A1 (ru) Оральная дозированная форма пропиверина
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
WO2005117895A8 (en) Compositions comprising meloxicam
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
DK1931316T3 (da) Farmaceutiske sammensætninger med kontrolleret afgivelse til syrelabile lægemidler
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
EA202192322A1 (ru) Фармацевтические составы
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
WO2005004915A3 (en) Compositions comprising meloxicam
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
CY1110572T1 (el) Στοματικο αντικαταθλιπτικο σκευασμα το οποιο περιλαμβανει ακετυλοσαλικυλικο οξυ για επιταχυνση της εναρξης δρασης
EA202193059A1 (ru) Фармацевтическая композиция
HRP20050466A2 (en) Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
MA55568A (fr) Compositions pharmaceutiques orodispersibles d'apixaban
MX2017014725A (es) Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.